Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 4/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15329099 | 1.00 | CHRM2 (0.43) | CHRM2CHRM1CHRM4CHRM5CHRM3 | |
| SCHEMBL8935489 | 0.92 | CHRM2 (0.44) | CHRM2CHRM1CHRM4CHRM3MEN1 | |
| SCHEMBL6965129 | 0.74 | CHRM2 (0.47) | CHRM2CHRM1CHRM4CHRM5CHRM3 | |
| Hydrochloric Acid SCHEMBL5200635 | 0.73 | ALDH1A1 (0.49) | CHRM2CHRM1CHRM4CHRM5CHRM3 | |
| SCHEMBL8236713 | 0.71 | CHRM2 (0.52) | CHRM2CHRM1CHRM4CHRM5CHRM3 | |
| SCHEMBL9967271 | 0.71 | CHRM2 (0.52) | CHRM2CHRM1CHRM4CHRM5CHRM3 | |
| SCHEMBL9698254 | 0.71 | CHRM1 (0.38) | CHRM2CHRM1CHRM4CHRM3MEN1 | |
| SCHEMBL28273440 | 0.71 | ALDH1A1 (0.49) | CHRM2CHRM1CHRM4CHRM5CHRM3 | |
| SCHEMBL15341643 | 0.71 | ALDH1A1 (0.46) | CHRM2CHRM1CHRM4CHRM5CHRM3 | |
| SCHEMBL9696817 | 0.70 | ALDH1A1 (0.46) | CHRM2CHRM1CHRM4CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295113-A1 | NLRP3 MODULATORS | ZOMAGEN BIOSCIENCES LTD | 2023-09-21 | — | — | US | disclosed |
| US-20230295113-A1 | NLRP3 MODULATORS | ZOMAGEN BIOSCIENCES LTD | 2023-09-21 | — | — | US | disclosed |
| WO-2023178099-A1 | NLRP3 MODULATORS | ZOMAGEN BIOSCIENCES LTD (US) | 2023-09-21 | — | — | WO | disclosed |
| EP-2758395-A1 | COMPOUNDS USEFUL AS INHIBITORS OF CHOLINE KINASE | Vertex Pharmaceuticals Inc. (US) | 2014-07-30 | — | — | EP | disclosed |
| US-20130281445-A1 | COMPOUNDS USEFUL AS INHIBITORS OF CHOLINE KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-24 | — | — | US | disclosed |
| US-20130281445-A1 | COMPOUNDS USEFUL AS INHIBITORS OF CHOLINE KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-24 | — | — | US | disclosed |
| US-20130281445-A1 | COMPOUNDS USEFUL AS INHIBITORS OF CHOLINE KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-24 | — | — | US | disclosed |
| WO-2013043960-A1 | COMPOUNDS USEFUL AS INHIBITORS OF CHOLINE KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013043960-A1 | COMPOUNDS USEFUL AS INHIBITORS OF CHOLINE KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-28 | — | — | WO | disclosed |
| US-5541194-A | PHARMACEUTICAL COMPOSTION USED TO TREAT DEMENTIA | BEECHAM GROUP P.L.C. (GB) | 1996-07-30 | — | — | US | disclosed |
| US-5324724-A | Azabicyclic compounds; Alzheimer's disease treatment | BEECHAM GROUP P.L.C. (GB) | 1994-06-28 | — | — | US | disclosed |
| US-5217975-A | AZABICYCLIC COMPOUNDS FOR TREATING DEMENTIA | BEECHAM GROUP P.L.C. (GB) | 1993-06-08 | — | — | US | disclosed |
| US-5091397-A | Cognition activators | BEECHAM GROUP P.L.C. (GB) | 1992-02-25 | — | — | US | disclosed |
| EP-0402056-A2 | Azabicyclic compounds, process for their preparation and pharmaceutical compositions containing them | Beecham Group p.l.c. (GB) | 1990-12-12 | — | — | EP | disclosed |
| EP-0322182-A2 | Azabicyclic compounds, process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1989-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281445-A1 | COMPOUNDS USEFUL AS INHIBITORS OF CHOLINE KINASE | CHKA, CHKB, PHKG1 | CHRM2 654/4885CHRM1 949/4885CHRM4 718/4885 |
| US-20230295113-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | CHRM2 4474/4885CHRM1 4579/4885CHRM4 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.